How Strong 2025 Results and MRD-Focused 2026 Guidance At Adaptive Biotechnologies (ADPT) Has Changed Its Investment Story

Simply Wall St.02-17

In early February 2026, Adaptive Biotechnologies reported full-year 2025 results showing sales of US$276.98 million versus US$178.96 million a year earlier, and a net loss of US$59.5 million versus US...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612452502?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-02-17 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612452502","market":"sg","top_or_hot":-1,"title":"How Strong 2025 Results and MRD-Focused 2026 Guidance At Adaptive Biotechnologies (ADPT) Has Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>In early February 2026, Adaptive Biotechnologies reported full-year 2025 results showing sales of US$276.98 million versus US$178.96 million a year earlier, and a net loss of US$59.5 million versus US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/how-strong-2025-results-and-mrd-focused-2026-guidance-at-ada\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Strong 2025 Results and MRD-Focused 2026 Guidance At Adaptive Biotechnologies (ADPT) Has Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Strong 2025 Results and MRD-Focused 2026 Guidance At Adaptive Biotechnologies (ADPT) Has Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-17 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/how-strong-2025-results-and-mrd-focused-2026-guidance-at-ada><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early February 2026, Adaptive Biotechnologies reported full-year 2025 results showing sales of US$276.98 million versus US$178.96 million a year earlier, and a net loss of US$59.5 million versus US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/how-strong-2025-results-and-mrd-focused-2026-guidance-at-ada\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/how-strong-2025-results-and-mrd-focused-2026-guidance-at-ada","article_id":"2612452502","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/how-strong-2025-results-and-mrd-focused-2026-guidance-at-ada","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612452502","pubTimestamp":1771327528,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early February 2026, Adaptive Biotechnologies reported full-year 2025 results showing sales of US$276.98 million versus US$178.96 million a year earlier, and a net loss of US$59.5 million versus US$159.49 million, with basic loss per share from continuing operations improving to US$0.39 from US$1.08.\nOn the same day, the company issued 2026 guidance for its measurable residual disease (MRD) business, projecting full-year revenue between US$255 million and US$265 million while withholding...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","MRD.AU":"MOUNT RIDLEY MINES LTD","BK7095":"多种金属与采矿","ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"Adaptive Biotechnologies(ADPT)2025年强劲业绩和以MRD为重点的2026年指导如何改变其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1.5,"MRD.AU":1},"content_text":"In early February 2026, Adaptive Biotechnologies reported full-year 2025 results showing sales of US$276.98 million versus US$178.96 million a year earlier, and a net loss of US$59.5 million versus US$159.49 million, with basic loss per share from continuing operations improving to US$0.39 from US$1.08. On the same day, the company issued 2026 guidance for its measurable residual disease (MRD) business, projecting full-year revenue between US$255 million and US$265 million while withholding outlook for its Immune Medicine segment, highlighting management’s current emphasis on MRD as the primary revenue engine. Next, we’ll consider how this combination of strong year-over-year revenue growth and focused MRD guidance could influence Adaptive’s investment narrative. AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementAdaptive Biotechnologies Investment Narrative RecapTo own Adaptive Biotechnologies, you need to believe its MRD platform can become a durable, scaled business while the broader company moves meaningfully closer to breakeven. The 2025 results show sharply higher revenue and a smaller net loss, which modestly eases near term concerns about prolonged unprofitability, but the 2026 MRD guidance also underlines how exposed the story still is to a single segment and to any disruption in MRD adoption or reimbursement. The most relevant recent announcement here is the December 2025 Pfizer collaboration, which ties directly into the MRD and immune profiling thesis. While Pfizer related milestones and data licensing are separate from the 2026 MRD revenue guide, they matter for the same set of catalysts: deeper pharma trial integration of clonoSEQ, potential milestone inflows, and broader validation of Adaptive’s immune medicine platform at a time when Immune Medicine guidance remains absent. Yet against this improving loss profile, investors should be aware that concentrated dependence on MRD and key partners could still... Read the full narrative on Adaptive Biotechnologies (it's free!)Adaptive Biotechnologies' narrative projects $350.6 million revenue and $49.8 million earnings by 2028. This requires 19.5% yearly revenue growth and a $171.0 million earnings increase from -$121.2 million today.Uncover how Adaptive Biotechnologies' forecasts yield a $20.14 fair value, a 26% upside to its current price.Exploring Other PerspectivesADPT 1-Year Stock Price Chart Before this update, the most optimistic analysts were assuming about 23 percent annual revenue growth and US$54.8 million of earnings by 2028, which is far more upbeat than the baseline view and could look either more achievable or more stretched once we see how the new MRD guidance and evolving partnership risks play through.Explore 3 other fair value estimates on Adaptive Biotechnologies - why the stock might be worth as much as 31% more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.Our free Adaptive Biotechnologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adaptive Biotechnologies' overall financial health at a glance.Seeking Other Investments?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Uncover the next big thing with 29 elite penny stocks that balance risk and reward.The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Find 55 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612452502","isCrawlerRequest":true}